R. Golz

发表

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

N. Willich, C. Rübe, T. Wiegel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis.

T. Wiegel, D. Bottke, A. Siegmann, 2013, European urology.

Prostatic specific antigen: immunoreactivity in urachal remnants.

R. Golz, G. Schubert, 1989, The Journal of urology.

Candidosis of the prostate: a rare form of endomycosis

R. Golz, W. Mendling, 1991, Mycoses.

Differential diagnosis of bladder versus colorectal adenocarcinoma: keratin 7 and GATA3 positivity in nuclear ß-catenin-negative glandular tumours defines adenocarcinoma of the bladder

K. Schwamborn, R. Knuechel, R. Golz, 2015, Journal of Clinical Pathology.

Appendix carcinoma invading the urinary bladder.

R. Golz, M. Hohenfellner, J. Thüroff, 1997, Urologia internationalis.

Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.

N. Willich, C. Rübe, T. Wiegel, 2014, European urology.

Multifocal adult rhabdomyoma. Case report and literature review.

R. Golz, 1988, Pathology, research and practice.

Comparative genomic profiling of glandular bladder tumours

G. Kristiansen, K. Schwamborn, R. Knuechel, 2020, Virchows Archiv.

Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.

C. Rübe, T. Wiegel, D. Bottke, 2015, International journal of radiation oncology, biology, physics.

Molecular Characterization of Muellerian Tumors of the Urinary Tract

R. Golz, M. Rose, N. Ortiz-Brüchle, 2021, Genes.

[Value of diffusion-weighted imaging for diagnosing vertebral metastases due to prostate cancer in comparison to other primary tumors].

T Hackländer, R. Golz, T. Hackländer, 2006, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer

R. Golz, N. Gaisa, R. Knüchel, 2022, Virchows Archiv.

Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer

R. Golz, R. Knüchel, F. von Rundstedt, 2021, Virchows Archiv.

Frequency of urogenital tuberculosis in an unselected autopsy series from 1928 to 1949 and 1976 to 1989.

R. Golz, G. Schubert, T. Haltaufderheide, 1992, European Urology.

Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/95): Ten years follow-up.

N. Willich, C. Rübe, D. Bottke, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OC-0047 PHASE III STUDY OF ADJUVANT RT FOR PROSTATE CANCER: IMPACT OF PATHOLOGIC REVIEW ON ANALYSIS

N. Willich, T. Wiegel, D. Bottke, 2012 .

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

N. Willich, C. Rübe, T. Wiegel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.

N. Willich, C. Rübe, T. Wiegel, 2014, European urology.